C-GXDCpeptidomimetics, broad-spectrum anti-infectives, innate immunity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Maxwell Biosciences presents the belief that its patented peptoid drug class could become a safe, effective, and potentially game-changing treatment for highly infectious pandemic viruses by irreversibly inactivating them. The company states that these anti-infectives mimic the naturally antiviral human peptide LL-37, may avoid meaningful viral resistance, have shown preclinical safety in human lung cells and mouse lungs, and work through a selective electrostatic attraction to negatively charged pathogens rather than healthy human cells.
SourceMaxwell Biosciences states that its CLAROMER brand small-molecule anti-infectives can directly attack the structure of viruses, destroying a broad spectrum of viral pathogens by disrupting viral membranes and binding viral DNA and RNA. The company presents this as a new therapeutic approach with broad-spectrum potential across viral, fungal, and bacterial pathogens, emphasizing preclinical efficacy, low toxicity, and a potentially favorable therapeutic window for treating otherwise hard-to-treat infections.
SourceMaxwell Biosciences presents itself as developing a new class of anti-infectives and antivirals that directly attack the structure of pathogens, especially viruses, rather than relying on conventional approaches. In the snapshot, the company frames the COVID-era viral pandemic as evidence of a major unmet need and claims its CLAROMER-branded compounds can broadly inactivate viruses based on preclinical studies and imaging of viral structures.
SourceMaxWell Biosciences presents itself as developing computer-assisted immunotherapeutic and AI-assisted personalized treatment plans to address drivers of cognitive impairment before permanent brain injury, with the stated belief that Alzheimer’s can be prevented, brain degeneration reversed, and brain performance optimized through the right multifactorial analysis and plan. It also frames young donor plasma and immunotherapy as promising avenues for chronic health issues and cognitive decline.
SourceMaxWell Biosciences states that cognitive impairment and brain degeneration can be addressed before permanent injury through computer-assisted immunotherapeutic solutions, personalized therapies, and artificial-intelligence-assisted multifactorial analysis and planning. The company also presents young donor plasma as a novel therapeutic avenue for chronic health issues and frames its work as aimed at preventing Alzheimer’s, reversing brain degeneration, and optimizing brain performance.
SourceMaxwell Biosciences states that antimicrobial-resistant bacteria are an urgent global threat and that its synthetic peptoid antibiotics could serve as a disruptive new antibacterial "silver bullet." The company says its peptoids rapidly kill a broad range of drug-resistant pathogens, are selective for pathogens over human cells, work at low doses, break down biofilms, and may help stop the cycle by which bacteria develop and share resistance.
Source